[News Space=Reporter seungwon lee] Samsung BioLogics, the world's largest bio contract development and manufacturing organization (CDMO), has celebrated its 14th anniversary. This year, Samsung BioLogics plans to continue its growth as a global top-tier bio company by accelerating its three-axis expansion strategy centered on production capacity, portfolio, and global bases.

Samsung BioLogics was established on April 21, 2011 in Songdo, Incheon. It was launched to fully promote the bio business, which Samsung Group selected as one of the 'five new growth businesses'. Despite being a latecomer to the global biopharmaceutical CDMO market, Samsung BioLogics quickly rose to become a leading company in the industry by rapidly securing production capacity and high quality competitiveness. The number of employees, which was only about 110 at the time of establishment, has now increased to about 5,000.

Currently, Samsung BioLogics' total production capacity is 784,000 liters, ranking first in the world. Since its establishment, the number of manufacturing approvals obtained from global regulatory agencies has exceeded 350, and the inspection pass rate is maintained at the highest level in the industry.

Based on its overwhelming production capacity and outstanding quality competitiveness, Samsung BioLogics has gained high trust from global pharmaceutical companies. Since its establishment, it has achieved orders for a total of 99 contract manufacturing (CMO) products and 133 contract development (CDO) products by the end of last year, and the cumulative order amount is 16.3 billion dollars.

In particular, last year, Samsung BioLogics signed three large contracts worth approximately KRW 1 trillion, achieving an annual order volume of KRW 5 trillion for the first time since its establishment. In January of this year, it succeeded in receiving orders worth KRW 2.747 trillion, the largest ever. Currently, it has secured 17 of the top 20 global big pharma companies as its clients.

Thanks to the order performance, sales are also growing at a very fast pace. In 2020, nine years after its establishment, it surpassed KRW 1 trillion in annual sales, and in 2022, it became the first domestic bio and pharmaceutical company to surpass KRW 3 trillion in annual sales, and in 2024, it surpassed KRW 4 trillion. This year, it is expected to grow by 20-25% year-on-year and surpass KRW 5 trillion.

Samsung BioLogics plans to continue to grow by focusing on expanding its three axes: ▲production capacity ▲portfolio ▲global base.

Samsung BioLogics, which began the era of the second bio campus with Plant 5, plans to build three additional plants of the same size as Plant 5 by 2032. When Plant 8 is completed, Samsung BioLogics’ total production capacity is expected to reach 1,324,000 liters, maintaining overwhelming competitiveness.

Portfolio diversification is also actively underway to secure growth momentum. Last month, the company began operating a dedicated production facility for antibody-drug conjugate (ADC) drugs, which are emerging as next-generation anticancer drugs, and plans to continue investing in new modalities such as cell and gene therapy (CGT) in the future.

We are also actively pursuing expansion of our overseas base. We operate sales offices in New Jersey, USA and Tokyo, Japan, and are strengthening our contact with major clients around the world.

Samsung BioLogics is receiving excellent evaluations from domestic and international ESG evaluation agencies and is also leading sustainable management in the global bio and pharmaceutical industry.

Last February, it received the highest 'Leadership' rating in the water security category from the Carbon Disclosure Project (CDP), a global sustainable management evaluation agency, and was included in the Dow Jones Sustainability Index (DJSI) 'World Index' for four consecutive years. In the 'Sustainable Markets Initiative' led by the British royal family to respond to climate change, CEO John Lim is directly serving as the chairman of the supply chain sector of the Health System Task Force (TF).

John Lim, CEO of Samsung BioLogics, said, “For the past 14 years, Samsung BioLogics has been leading the CDMO market by providing the best quality and service to global customers.” He added, “We will continue to make preemptive investments to further enhance competitiveness, and all executives and employees will do their best to realize the company’s vision of contributing to a better life for humanity.”